Premium
IC‐P‐015: VOXEL‐BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM
Author(s) -
Salvadó Gemma,
Collij Lyduine,
Niñerola-Baizán Aida,
Perissinotti Andrés,
Flier Wiesje M.,
Visser Pieter Jelle,
Scheltens Philip,
Zetterberg Henrik,
Blennow Kaj,
Barkhof Frederik,
Molinuevo Jose Luis,
Alves Isadora Lopes,
Gispert Juan Domingo
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4177
Subject(s) - voxel , abnormality , nuclear medicine , stage (stratigraphy) , medicine , histogram , cohort , psychology , radiology , pathology , artificial intelligence , computer science , biology , psychiatry , paleontology , image (mathematics)
abnormal amyloid biomarkers are possible, with either CSF or PET becoming abnormal first (Figure 2). The hypothesis whereby CSF represents a dynamic measure of ongoing amyloid accumulation may only partially account for biomarkers mismatches. Since amyloid PET tracers primarily bind to dense-core fibrillary plaques and not to protofibrils or oligomers, biological factors underlying individual differences in the conformation of amyloid aggregates may partly explain the observed discordance, advocating for the need for diverse biomarkers for patient stratification.